33 results about "Taking blood sample" patented technology

The invention discloses a newborn rare disease intelligent screening and diagnosis system based on multi-omics data fusion, relates to the technical field of medical data processing, and aims to solve the technical problems that a traditional diagnosis method is long in time consumption and low in accuracy and cannot meet the requirement for rapid and accurate diagnosis of newborn rare diseases. The data acquisition module is used for acquiring clinical omics data from a doctor's advice database through a neonatal medical record, and acquiring blood samples to acquire gene data and metabonomics data and marking when the medical record records that the neonatal suffers from a rare disease; the data processing module is used for preprocessing the clinical omics data according to the neonatal medical record to obtain a training set and a test set, and preprocessing the gene data and the metabonomics data according to the blood sample; and the diagnosis module is connected with the data processing module. By constructing a three-level modular architecture, the problem of missed diagnosis caused by traditional multi-source data isolated analysis is effectively solved, and the accuracy rate of newborn rare disease diagnosis is remarkably improved.

1. The name of the design product: collection tube. 2. The use of the design product: for hospital patients to collect blood samples. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1. 5. Other circumstances that need to be explained: part A is transparent material.

Apparatus and methods are described including a microscope system configured to acquire first and second images of a blood sample at respective times. A computer processor determines whether, between acquisitions of the first and second images, there was motion of a given entity within the sample, by comparing the first and second images to one another. At least partially in response thereto, the computer processor distinguishes between the given entity being a non-parasitic entity and the given entity being a parasite, and generates an output on the output device, at least partially in response thereto. Other applications are also described.

1. The name of the design product: blood sampling pen. 2. The use of the design product: instrument for collecting blood samples. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view 1.

The invention discloses a dynamic algorithm for blood culture positive judgment, which comprises the following steps: S1, data acquisition: a blood volume monitoring module is arranged on a blood culture bottle, and the module adopts at least one of a pressure sensor, a weight sensor or a visual system to monitor the liquid level height and is used for accurately measuring the blood collection volume; after a collected blood sample is injected into the blood culture bottle, the blood volume monitoring module obtains blood collection volume data in real time. According to the invention, the blood volume monitoring module is added to realize accurate measurement of the blood collection volume, a scientific relation model is established by using big data analysis, and a dynamic positive judgment model based on sample information is constructed. According to the algorithm, a dynamic positive judgment threshold value can be calculated according to real-time data, the false positive rate caused by too much blood sampling amount or too much leukocytes of a patient is effectively reduced, the accuracy and timeliness of blood culture detection are remarkably improved, a more reliable basis is provided for clinical diagnosis, doctors are assisted to formulate a reasonable treatment scheme in time, and the treatment effect is improved. The treatment effect and the survival rate of patients are improved.

The invention relates to the technical field of poultry health assessment, in particular to a method for predicting and identifying the high fat deposition risk of the liver of a laying hen based on blood amino acid parameters. The method comprises the following steps: collecting a blood sample when the laying hen is in a metabolic state after absorption, detecting the total amino acid content and the alanine content in blood, and substituting blood parameters into a pre-established liver triglyceride prediction model to obtain the predicted liver triglyceride content, and comparing the prediction results to judge the high fat deposition risk of the liver of the laying hen. According to the method, the laying hens do not need to be slaughtered and sampled, the fat deposition state of the livers of the living laying hens can be rapidly evaluated, and the method is suitable for early screening and risk early warning of high fat deposition of the livers of the laying hens under the large-scale breeding condition.

Blood sample optimization systems and methods are described that reduce or eliminate contaminates in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. A blood sample optimization system can include a blood sequestration device located between a patient needle and a sample needle. The blood sequestration device can include a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.

This application relates to a sample analyzer and a sample analysis method. A sampling distribution module is configured to collect blood samples and allocate a portion of the collected blood samples to an erythrocyte sedimentation rate (ESR) detection module. The ESR detection module's optical detection device detects the ESR of the blood sample by detecting the degree of light absorption or scattering by a portion of the blood sample. When the detection mode is in the first mode, the control module controls the sampling distribution module to allocate a first amount of the blood sample to the ESR detection module and controls the ESR motor to drive the first amount of the blood sample to the detection location at a first speed. When the detection mode is in the second mode, the control module controls the sampling distribution module to allocate a second amount of the blood sample to the ESR detection module and controls the ESR motor to drive the second amount of the blood sample to the detection location at a second speed. The second amount is smaller than the first amount, and the second speed is smaller than the first speed. This ensures that the precision of the ESR detection remains essentially constant under different blood volumes.

Disclosed are a blood analysis system, method, device, and computer storage medium. The blood analysis system includes: a sample collection device for collecting a blood sample and transferring the blood sample to a sample preparation device; a sample preparation device for processing the blood sample using a reagent to prepare a sample solution to be tested; an impedance detection device for detecting the sample solution to be tested to obtain an impedance pulse signal of cells in the sample solution to be tested; and a data processing device for performing the following steps: obtaining a blood cell histogram of the sample solution to be tested based on the impedance pulse signal, inputting the blood cell histogram into a pre-trained deep learning neural network model to obtain blood cell parameters output by the deep learning neural network model, wherein the blood cell parameters are at least one of the following: a reticulocyte parameter, a reticulocyte platelet parameter, and a red blood cell fragment parameter; and the deep learning neural network model is obtained by training blood training samples labeled with blood cell parameters using a machine learning algorithm.

The invention discloses a malaria pathogen detection system based on an improved YOLO algorithm. The malaria pathogen detection system comprises a blood sampling module, a microfluidic processing module, a microscopic imaging module, an AI analysis module and a display screen, the blood sampling module is used for quickly collecting a blood sample from a fingertip; the microfluidic processing module is used for integrating a thin film heater and accurately controlling the temperature of a sample; the microscopic imaging module is used for integrating a Raspberry Pi HQ Camera module and an automatic focusing motor MEMS (Micro Electro Mechanical System) micromirror, and converting a blood sample into a digital image through a high-precision lens and a dynamic focusing function; the AI analysis module is used for internally arranging an improved lightweight YOLO algorithm and carrying out efficient image processing and real-time pathogen detection in the equipment; and the display screen is used for outputting a real-time detection result and confidence in a two-stage display mode by using an OLED (Organic Light Emitting Diode) screen. According to the invention, the accuracy of disease detection is obviously improved.

The invention discloses a cardiovascular and cerebrovascular disease screening system and method based on collaborative acquisition, relates to the technical field of screening data, and is used for solving the problem of triggering logic separation, completing preliminary screening according to a preset screening rule by calling family history information in an electronic health record, marking a target user and accessing a screening evaluation mechanism, and obtaining a screening result. If not, a risk mark is directly generated, carotid plaque ultrasonic imaging and hemodynamic monitoring are carried out on the target user, plaque density parameters are calculated and fused with hemodynamic data to form user state feature values, the user state feature values are classified as abnormal users, and blood samples are collected through a biological index calibration module; the erythrocyte distribution width and the brain natriuretic peptide hormone content are detected, the erythrocyte mutation rate is calculated, the brain natriuretic peptide is combined to generate the calibration proportion, the state characteristic value is corrected, the corrected characteristic value is formed and compared with the risk threshold value to generate the risk mark, the risk screening accuracy and sensitivity are improved, and the omission ratio and the misjudgment rate are reduced.

A method of analyzing a blood sample from a subject includes loading the blood sample into a single chamber; acquiring, via an imaging system, a stack of serial focal plane images of the blood sample from a plurality of fields of view of the chamber; creating a virtual three dimensional image of the blood sample from selected ones of the stacks of serial focal plane images; and analyzing the virtual three dimensional image to identify blood formed elements within the blood sample. Identifying blood formed elements within the blood sample may include identifying a type and amount of white blood cells, and / or identifying an amount of red blood cells and / or hematocrit, and / or identifying an amount of platelets. Identifying blood formed elements within the blood sample may include determining numbers and percentage by volume in the blood sample of one or more types of white blood cells.

The present invention provides a blood analyzer, which comprises: a sampling distribution module, which comprises a sampling device for collecting a blood sample and a sample separation device, the sampling device comprises a sampling needle and a first power device, the first power device is used for driving the sampling needle to collect the blood sample, and the sample separation device is used for separating the blood sample from the sampling needle; and the sample separating device is used for distributing the collected blood samples to different detection modules. The isolation air column is arranged between the sampling needle and the diluent, so that the blood sample is diluted as little as possible, and the measurement precision is improved.

The utility model relates to the technical field of blood concentration detection, and discloses a blood concentration mass spectrum detection auxiliary device, which comprises a main body, four corners of the bottom of the main body are respectively and fixedly connected with a support rod, and the main body is provided with a refrigeration storage mechanism. According to the utility model, by starting the four semiconductor chilling plates, the cold energy generated by the cold ends of the semiconductor chilling plates is transmitted to the cold conduction copper block, and the cold conduction copper block transmits the cold energy into the storage cavity, so that the temperature of the storage cavity is reduced, a blood sample on the object placing plate is uniformly cooled, and the uniformity of the sample storage temperature is ensured; the device is simple in structure and convenient to operate, instability of medicine components in a sample due to temperature difference is avoided, medicine degradation, deterioration or chemical reaction is effectively prevented, the accuracy of a detection result is ensured, the electric hydraulic cylinder is started to drive the storage plate to move up and down, the height of the storage plate can be conveniently adjusted, the blood sample can be conveniently placed and taken, and the operation convenience is improved.

The present invention provides a blood analyzer comprising: a sampling and distribution module, including a sampling device for collecting blood samples and a sample separation device, the sampling device including a sampling needle and a first power device, the first power device being used to drive the sampling needle to collect the blood sample, and the sample separation device being used to distribute the collected blood sample to different detection modules. An isolation gas column is provided between the sampling needle and a diluent to minimize dilution of the blood sample, or the erythrocyte sedimentation rate detection module is positioned stationary relative to the sampling needle, thereby shortening the connecting pipeline between the two and reducing blood sample loss, thereby improving measurement accuracy.

A blood sampler (1) for taking a blood sample from a finger (61), comprising: a clip (2) having a first opening (21) for defining a space (20) for receiving at least a portion of the finger (61) and for attaching a vial (3) for receiving the blood sample; and at least one lancet holder (5) for receiving a lancet system (4) including a lancet (43) for cutting at least a portion of the finger when at least a portion of the finger is in the space (20), located inside or on the clip (2) but different from the first opening (21).

The invention provides a blood sample quantitative extraction device, and relates to the field of medical instruments. The quantitative blood sample extraction device comprises an extraction structure, a collection structure is arranged at the lower end of the extraction structure, and the upper end of the collection structure is detachably connected with the lower end of the extraction structure. By arranging an extraction structure, during use, a screw rod is driven to rotate by rotating a rotary cover, a piston plate is driven to move upwards by utilizing a threaded connection relationship between the screw rod and a connecting disc, and the amount of an internal collected blood sample is adjusted by matching with a graduated scale on the side wall of a sleeve; and in cooperation with the material characteristics of a first sealing gasket, a second sealing gasket and a third sealing gasket, it can be guaranteed that the device is not affected by the outside after collection and in the collection process, the safety in the collection process is guaranteed, after collection is completed, a positioning rod is pressed downwards, rotation of a rotating cover is limited, and the collection efficiency is improved. And the risk of tampering the internal samples in the transportation process can be avoided.

The application discloses a blood analyzer and a detection method thereof, wherein the blood analyzer comprises a sampling module, a routine blood test module and a specific protein detection module; wherein: the sampling module is used for collecting a blood sample, and the blood sample is added to the routine blood test module; the routine blood test module is used for diluting the blood sample; the sampling module adds the diluted blood sample to the specific protein detection module; and the specific protein detection module is used for detecting specific proteins in the diluted blood sample. Through the above mode, the blood sample is diluted by the routine blood test module, so that the specific protein concentration of the blood sample is prevented from being too high, and the accuracy of the blood analyzer detection is improved.

A sampling barrel is connected with a sampling device through a threaded structure, a blood sampling assembly is located at the bottom of the sampling device, the sampling device comprises a connecting barrel, connecting rods are arranged on the upper side and the lower side of the connecting barrel, and a rubber pad is clamped to the bottom of the connecting rod located on the lower side; a connecting plate is clamped to the bottom of the rubber pad, the blood sampling assembly is located at the bottom of the connecting plate and comprises a fixing cylinder, sliding grooves are formed in the two sides of an inner cavity of the fixing cylinder, sliding blocks are arranged in the sliding grooves, springs are connected to the bottoms of the sliding blocks, limiting cylinders are fixedly connected to the bottoms of the springs, and blood sampling needles are connected to the bottoms of the springs; an arc-shaped limiting groove is formed in the outer side of the fixing cylinder, and a limiting column connected with the arc-shaped limiting groove is connected to the spring. Compared with the prior art, the blood sampling device has the advantages that the sampling barrel and the blood sampling needle are combined, blood sampling can be better carried out on a patient, the cost is saved, and meanwhile the practicability is improved.

The application discloses a set of applications of glycosylation related gene markers in liver cancer detection and belongs to the technical field of biotechnology.The glycosylation related gene markers are composed of five types of 10 genes, namely, neuraminidase 1 (NEU1), N-acetylneuraminic acid synthase (NANS), cytidine monophosphate N-acetylneuraminic acid hydroxylase (CMAH), solute carrier family 35 member A1 (SLC35A1) and glycosyltransferase (B3GALT4, B3GALNT2, ALG2, MGAT2, FUT8 and ST3GAL2). The application first uses the markers as liver cancer diagnostic markers for liver cancer detection, and the average AUC of liver cancer can reach 82.14% through combined diagnosis of the multiple indexes of the set of genes.Compared with AFP which is widely used at present, the sensitivity and specificity of diagnosis can be greatly improved, and the technology still takes blood samples as the main detection target, and does not cause secondary damage to patients, the technology provides a new technical platform and means for clinical detection of liver cancer, and has a strong practical application value.

The invention discloses a metabolic marker composition for early thyroid cancer detection and application thereof, and relates to the technical field of biomedicine, and the metabolic marker composition for early thyroid cancer detection comprises sphingosine 1-phosphate, L-ornithine, pyroglutamic acid and L-valyl-L-serine. The metabolic marker composition provided by the invention has high sensitivity and high specificity when being used for detecting the early thyroid cancer, and can realize detection and screening of the early thyroid cancer. Meanwhile, when the metabolic marker composition is used for early thyroid cancer detection, operation is easy, sample obtaining is convenient, cost is low, a non-invasive detection mode is adopted, only blood samples need to be collected, safety and reliability are achieved, and patient compliance is high.

An integrated venous catheter can have a side port that facilitates blood withdrawal. The side port provides a separate fluid pathway for blood withdrawal and for infusion of fluid via an extension set. The side port can be configured to allow priming of the extension set while a blood sample is being collected. In this way, it is facilitated to collect a blood sample upon catheter insertion.

1. The name of the design product: blood sampling pen without removing cap. 2. The use of the design product: instrument for collecting blood sample. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

The invention relates to a sensor skin implant, use of such a sensor skin implant, a method for detecting the presence of an analyte with such a sensor skin implant and a method for manufacturing of such a sensor skin implant. Implantable sensors can accompany medical treatments, easing the life of both physicians and patients by providing a comfortable way of continuously monitoring biomarkers without needing to take blood samples. For ideal sensor read-out and comparison of measurement results between patients, the individual implants must be as uniform as possible to exclude the influence of measurement artifacts caused by differences between implants. Additionally, the integration of the implant into the host tissue must be ensured for every single case to guarantee unrestricted analyte transport to the sensor and prevent non-working implants. The object of the invention was in particular to find a new fabrication approach to produce nanoparticle-based macroporous implants enabling mass production with improved implant quality and a new method for detecting the presence of an analyte with such a sensor skin implant that shows a better or easier sensor read-out. The invention solves this task particularly with a sensor skin implant comprising a plurality of alternating reference stripes and sensor stripes that are arranged next to each other to form a repetition unit, wherein the sensor stripes and references stripes are embedded in a bio- integrable macroporous hydrogel and are equipped with one type of nanoparticles, wherein the nanoparticles of the sensor stripes are coupled to or coated with a receptor bearing specific binding sites for an analyte.

The invention relates to the technical field of medical apparatus and instruments, in particular to a method and device for treating intrahepatic cholestasis in a gestation period through targeted mitochondrial autophagy regulation and control, and the method comprises the following steps: step 1, blood sample collection: collecting a blood sample, and detecting the content of mitochondrial autophagy related biomarkers; 2, data analysis: inputting detection data into a data analysis model, and evaluating the disease risk degree; 3, comprehensive diagnosis: making a diagnosis result according to the risk degree of intrahepatic cholestasis of the patient in the gestation period in combination with clinical symptoms of the patient; and step 4, formulating a treatment scheme: formulating a targeted mitochondrial autophagy regulation and control treatment scheme when the patient is diagnosed as intrahepatic cholestasis in the gestation period according to a diagnosis result. In the diagnosis process of intrahepatic cholestasis in the gestation period, the accuracy and stability of a blood sample can be improved, and sample errors caused by manual operation are reduced.

The present invention discloses a method for detecting the penumbra of acute ischemic stroke based on in vitro serum molecular markers, belonging to the field of biotechnology. This detection method is an operation of detecting glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in a sample to be detected as biomarkers, including: (1) Sample collection: Collecting a blood sample and centrifuging to separate the serum; (2) Sample detection: Using a kit to detect the contents of GFAP and UCH-L1 in the sample; (3) Analysis of detection results: Calculating the ratio of GFAP to UCH-L1 through analysis software and analyzing its correlation with the penumbra of acute ischemic stroke. This method can quantify the levels of bedside serum GFAP and UCH-L1 within a short time (within 28 minutes), providing rapid biomarker detection results for clinical practice. This detection method is more economical, reduces medical costs, and has broad clinical application prospects.

This invention provides an AI-based user nutrition detection and intervention system and method. The system enables non-invasive multimodal detection without the need for blood sample collection, addressing the invasiveness and inefficiency issues of traditional clinical testing. Through feature-level fusion and deep neural network processing, it achieves collaborative analysis of BIA body composition, respiratory features, body shape data, and voice interaction information, improving the accuracy of risk level classification compared to single-modal models. The voice interaction process is optimized for special groups such as the elderly and children, employing beamforming noise reduction technology and the ERNIE-Speech voice recognition model to overcome the operational barriers of traditional devices. Intervention plans are generated based on user dietary preferences and physiological characteristics. AES encryption and blockchain notarization technologies ensure the immutability of user privacy data, complying with the Personal Information Protection Law and addressing data security vulnerabilities of existing devices.

The utility model discloses an arc-shaped blood glucose electronic test paper for rapidly collecting blood samples, which comprises a collecting strip, a base plate, a sampling area, an insulating plate and a capillary layer, the sampling end of the collecting strip is arc-shaped, the base plate is fixedly arranged inside the collecting strip, the sampling area is fixedly arranged on the base plate, and the insulating plate is fixedly arranged on the collecting strip. The insulating plate is fixedly installed in the collecting strip, the thin capillary tube layer is fixedly installed on the insulating plate, and the thin capillary tube layer is located over the sampling area. The sampling end of the sampling strip is arranged in an arc shape, so that a user can conveniently collect blood, the blood of fingers is squeezed or scraped on the sampling window by the user, and then the blood quickly penetrates through the thin capillary layer, so that the blood quickly reaches a sampling area, and the situation that the blood cannot completely cover the whole sampling area is avoided; meanwhile, the situation that the blood cannot be fully diffused to the whole sampling area due to insufficient blood sucking capacity of the test paper, so that the measurement result is influenced is avoided.

This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

This invention discloses a cardiovascular and cerebrovascular disease screening system and method based on collaborative data acquisition, belonging to the field of screening data technology. It addresses the problem of trigger logic separation by retrieving family history information from electronic health records, performing initial screening according to preset screening rules, marking target users and passing them into the screening assessment mechanism, while generating risk markers directly for non-target users. For target users, carotid artery plaque ultrasound imaging and hemodynamic monitoring are performed, plaque density parameters are calculated, and hemodynamic data are fused to form user status feature values. Users classified as abnormal undergo blood sample collection via a biometric calibration module to detect erythrocyte distribution width and brain natriuretic peptide (BNP) levels, calculate erythrocyte mutation rate, and combine it with BNP to generate a calibration ratio. The status feature values ​​are then corrected, forming corrected feature values ​​that are compared with a risk threshold to generate risk markers, improving the accuracy and sensitivity of risk screening and reducing false negative and false positive rates.